As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) ...

Some say that AI’s potential in drug development is overstated. Others say that it is, if anything, understated. Who is right? Only time will tell. In the meantime, both sides—and the ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

Insilico Medicine announced results from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease ...

Insilico used AI to identify a new IPF target and create a new molecule to interact with that target. The company used PandaOmics to identify disease-causing targets and Chemistry42 to design new ...